[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

United States Multiple Sclerosis (MS) Drugs Market Report 2017

December 2017 | 105 pages | ID: UD6BF08BD8BEN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In this report, the United States Multiple Sclerosis (MS) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
  • The West
  • Southwest
  • The Middle Atlantic
  • New England
  • The South
  • The Midwest
  • with sales (volume), revenue (value), market share and growth rate of Multiple Sclerosis (MS) Drugs in these regions, from 2012 to 2022 (forecast).
United States Multiple Sclerosis (MS) Drugs market competition by top manufacturers/players, with Multiple Sclerosis (MS) Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
  • Bayer AG
  • Bayhill Therapeutics
  • Biogen Idec
  • Cinnagen
  • Daiichi Sankyo
  • Eli Lilly
  • Fast Forward Llc
  • Antisense Therapeutics
  • Apitope
  • Five Prime Therapeutics
  • Genmab
  • Artielle Immunotherapeutics
  • Genzyme
  • Glaxosmithkline
  • Gw Pharmaceuticals
  • Innate Immunotherapeutics
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
  • Copaxone (Glatiramer Acetate, Copolymer 1)
  • Novantrone (Mitoxantrone)
  • Gilenya (Fingolimod, Fty720)
  • Aubagio (Teriflunomide)
  • Tecfidera (Dimethyl Fumarate)
  • Firategrast (Sb683699, T-0047)
  • Siponimod (Baf312)
  • Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
  • RRMS
  • SPMS
  • PPMS
  • PRMS
If you have any special requirements, please let us know and we will offer you the report as you want.
United States Multiple Sclerosis (MS) Drugs Market Report 2017

1 MULTIPLE SCLEROSIS (MS) DRUGS OVERVIEW

1.1 Product Overview and Scope of Multiple Sclerosis (MS) Drugs
1.2 Classification of Multiple Sclerosis (MS) Drugs by Product Category
  1.2.1 United States Multiple Sclerosis (MS) Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Multiple Sclerosis (MS) Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Copaxone (Glatiramer Acetate, Copolymer 1)
  1.2.4 Novantrone (Mitoxantrone)
  1.2.5 Gilenya (Fingolimod, Fty720)
  1.2.6 Aubagio (Teriflunomide)
  1.2.7 Tecfidera (Dimethyl Fumarate)
  1.2.8 Firategrast (Sb683699, T-0047)
  1.2.9 Siponimod (Baf312)
  1.2.10 Others
1.3 United States Multiple Sclerosis (MS) Drugs Market by Application/End Users
  1.3.1 United States Multiple Sclerosis (MS) Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 RRMS
  1.3.3 SPMS
  1.3.4 PPMS
  1.3.5 PRMS
1.4 United States Multiple Sclerosis (MS) Drugs Market by Region
  1.4.1 United States Multiple Sclerosis (MS) Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Multiple Sclerosis (MS) Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest Multiple Sclerosis (MS) Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Multiple Sclerosis (MS) Drugs Status and Prospect (2012-2022)
  1.4.5 New England Multiple Sclerosis (MS) Drugs Status and Prospect (2012-2022)
  1.4.6 The South Multiple Sclerosis (MS) Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest Multiple Sclerosis (MS) Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Multiple Sclerosis (MS) Drugs (2012-2022)
  1.5.1 United States Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES MULTIPLE SCLEROSIS (MS) DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Multiple Sclerosis (MS) Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Multiple Sclerosis (MS) Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Multiple Sclerosis (MS) Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Multiple Sclerosis (MS) Drugs Market Competitive Situation and Trends
  2.4.1 United States Multiple Sclerosis (MS) Drugs Market Concentration Rate
  2.4.2 United States Multiple Sclerosis (MS) Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Multiple Sclerosis (MS) Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES MULTIPLE SCLEROSIS (MS) DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Multiple Sclerosis (MS) Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Multiple Sclerosis (MS) Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Multiple Sclerosis (MS) Drugs Price by Region (2012-2017)

4 UNITED STATES MULTIPLE SCLEROSIS (MS) DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Multiple Sclerosis (MS) Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Multiple Sclerosis (MS) Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Multiple Sclerosis (MS) Drugs Price by Type (2012-2017)
4.4 United States Multiple Sclerosis (MS) Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES MULTIPLE SCLEROSIS (MS) DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Multiple Sclerosis (MS) Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Multiple Sclerosis (MS) Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES MULTIPLE SCLEROSIS (MS) DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Bayer AG
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Bayhill Therapeutics
  6.2.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Biogen Idec
  6.3.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Cinnagen
  6.4.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Daiichi Sankyo
  6.5.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Eli Lilly
  6.6.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Fast Forward Llc
  6.7.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Antisense Therapeutics
  6.8.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Apitope
  6.9.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Five Prime Therapeutics
  6.10.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Genmab
6.12 Artielle Immunotherapeutics
6.13 Genzyme
6.14 Glaxosmithkline
6.15 Gw Pharmaceuticals
6.16 Innate Immunotherapeutics

7 MULTIPLE SCLEROSIS (MS) DRUGS MANUFACTURING COST ANALYSIS

7.1 Multiple Sclerosis (MS) Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Multiple Sclerosis (MS) Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES MULTIPLE SCLEROSIS (MS) DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Multiple Sclerosis (MS) Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Multiple Sclerosis (MS) Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Multiple Sclerosis (MS) Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Multiple Sclerosis (MS) Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES

Figure Product Picture of Multiple Sclerosis (MS) Drugs
Figure United States Multiple Sclerosis (MS) Drugs Market Size (K Pcs) by Type (2012-2022)
Figure United States Multiple Sclerosis (MS) Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Copaxone (Glatiramer Acetate, Copolymer 1) Product Picture
Figure Novantrone (Mitoxantrone) Product Picture
Figure Gilenya (Fingolimod, Fty720) Product Picture
Figure Aubagio (Teriflunomide) Product Picture
Figure Tecfidera (Dimethyl Fumarate) Product Picture
Figure Firategrast (Sb683699, T-0047) Product Picture
Figure Siponimod (Baf312) Product Picture
Figure Others Product Picture
Figure United States Multiple Sclerosis (MS) Drugs Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of Multiple Sclerosis (MS) Drugs by Application in 2016
Figure RRMS Examples
Table Key Downstream Customer in RRMS
Figure SPMS Examples
Table Key Downstream Customer in SPMS
Figure PPMS Examples
Table Key Downstream Customer in PPMS
Figure PRMS Examples
Table Key Downstream Customer in PRMS
Figure United States Multiple Sclerosis (MS) Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Multiple Sclerosis (MS) Drugs Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States Multiple Sclerosis (MS) Drugs Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States Multiple Sclerosis (MS) Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Multiple Sclerosis (MS) Drugs Sales Share by Players/Suppliers
Figure 2017 United States Multiple Sclerosis (MS) Drugs Sales Share by Players/Suppliers
Figure United States Multiple Sclerosis (MS) Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Multiple Sclerosis (MS) Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Multiple Sclerosis (MS) Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Multiple Sclerosis (MS) Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Multiple Sclerosis (MS) Drugs Revenue Share by Players/Suppliers
Table United States Market Multiple Sclerosis (MS) Drugs Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market Multiple Sclerosis (MS) Drugs Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States Multiple Sclerosis (MS) Drugs Market Share of Top 3 Players/Suppliers
Figure United States Multiple Sclerosis (MS) Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Multiple Sclerosis (MS) Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Multiple Sclerosis (MS) Drugs Product Category
Table United States Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Region (2012-2017)
Table United States Multiple Sclerosis (MS) Drugs Sales Share by Region (2012-2017)
Figure United States Multiple Sclerosis (MS) Drugs Sales Share by Region (2012-2017)
Figure United States Multiple Sclerosis (MS) Drugs Sales Market Share by Region in 2016
Table United States Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Multiple Sclerosis (MS) Drugs Revenue Share by Region (2012-2017)
Figure United States Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2012-2017)
Figure United States Multiple Sclerosis (MS) Drugs Revenue Market Share by Region in 2016
Table United States Multiple Sclerosis (MS) Drugs Price (USD/Pcs) by Region (2012-2017)
Table United States Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2012-2017)
Table United States Multiple Sclerosis (MS) Drugs Sales Share by Type (2012-2017)
Figure United States Multiple Sclerosis (MS) Drugs Sales Share by Type (2012-2017)
Figure United States Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2016
Table United States Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Multiple Sclerosis (MS) Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Multiple Sclerosis (MS) Drugs by Type (2012-2017)
Figure Revenue Market Share of Multiple Sclerosis (MS) Drugs by Type in 2016
Table United States Multiple Sclerosis (MS) Drugs Price (USD/Pcs) by Types (2012-2017)
Figure United States Multiple Sclerosis (MS) Drugs Sales Growth Rate by Type (2012-2017)
Table United States Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Application (2012-2017)
Table United States Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2012-2017)
Figure United States Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2012-2017)
Figure United States Multiple Sclerosis (MS) Drugs Sales Market Share by Application in 2016
Table United States Multiple Sclerosis (MS) Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Multiple Sclerosis (MS) Drugs Sales Growth Rate by Application (2012-2017)
Table Bayer AG Basic Information List
Table Bayer AG Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Bayer AG Multiple Sclerosis (MS) Drugs Sales Growth Rate (2012-2017)
Figure Bayer AG Multiple Sclerosis (MS) Drugs Sales Market Share in United States (2012-2017)
Figure Bayer AG Multiple Sclerosis (MS) Drugs Revenue Market Share in United States (2012-2017)
Table Bayhill Therapeutics Basic Information List
Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales Growth Rate (2012-2017)
Figure Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales Market Share in United States (2012-2017)
Figure Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Revenue Market Share in United States (2012-2017)
Table Biogen Idec Basic Information List
Table Biogen Idec Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Biogen Idec Multiple Sclerosis (MS) Drugs Sales Growth Rate (2012-2017)
Figure Biogen Idec Multiple Sclerosis (MS) Drugs Sales Market Share in United States (2012-2017)
Figure Biogen Idec Multiple Sclerosis (MS) Drugs Revenue Market Share in United States (2012-2017)
Table Cinnagen Basic Information List
Table Cinnagen Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Cinnagen Multiple Sclerosis (MS) Drugs Sales Growth Rate (2012-2017)
Figure Cinnagen Multiple Sclerosis (MS) Drugs Sales Market Share in United States (2012-2017)
Figure Cinnagen Multiple Sclerosis (MS) Drugs Revenue Market Share in United States (2012-2017)
Table Daiichi Sankyo Basic Information List
Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales Growth Rate (2012-2017)
Figure Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales Market Share in United States (2012-2017)
Figure Daiichi Sankyo Multiple Sclerosis (MS) Drugs Revenue Market Share in United States (2012-2017)
Table Eli Lilly Basic Information List
Table Eli Lilly Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Eli Lilly Multiple Sclerosis (MS) Drugs Sales Growth Rate (2012-2017)
Figure Eli Lilly Multiple Sclerosis (MS) Drugs Sales Market Share in United States (2012-2017)
Figure Eli Lilly Multiple Sclerosis (MS) Drugs Revenue Market Share in United States (2012-2017)
Table Fast Forward Llc Basic Information List
Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales Growth Rate (2012-2017)
Figure Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales Market Share in United States (2012-2017)
Figure Fast Forward Llc Multiple Sclerosis (MS) Drugs Revenue Market Share in United States (2012-2017)
Table Antisense Therapeutics Basic Information List
Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales Growth Rate (2012-2017)
Figure Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales Market Share in United States (2012-2017)
Figure Antisense Therapeutics Multiple Sclerosis (MS) Drugs Revenue Market Share in United States (2012-2017)
Table Apitope Basic Information List
Table Apitope Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Apitope Multiple Sclerosis (MS) Drugs Sales Growth Rate (2012-2017)
Figure Apitope Multiple Sclerosis (MS) Drugs Sales Market Share in United States (2012-2017)
Figure Apitope Multiple Sclerosis (MS) Drugs Revenue Market Share in United States (2012-2017)
Table Five Prime Therapeutics Basic Information List
Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales Growth Rate (2012-2017)
Figure Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales Market Share in United States (2012-2017)
Figure Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Revenue Market Share in United States (2012-2017)
Table Genmab Basic Information List
Table Artielle Immunotherapeutics Basic Information List
Table Genzyme Basic Information List
Table Glaxosmithkline Basic Information List
Table Gw Pharmaceuticals Basic Information List
Table Innate Immunotherapeutics Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Multiple Sclerosis (MS) Drugs
Figure Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs
Figure Multiple Sclerosis (MS) Drugs Industrial Chain Analysis
Table Raw Materials Sources of Multiple Sclerosis (MS) Drugs Major Players/Suppliers in 2016
Table Major Buyers of Multiple Sclerosis (MS) Drugs
Table Distributors/Traders List
Figure United States Multiple Sclerosis (MS) Drugs Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Multiple Sclerosis (MS) Drugs Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States Multiple Sclerosis (MS) Drugs Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Multiple Sclerosis (MS) Drugs Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Multiple Sclerosis (MS) Drugs Sales Volume (K Pcs) Forecast by Type in 2022
Table United States Multiple Sclerosis (MS) Drugs Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Multiple Sclerosis (MS) Drugs Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Multiple Sclerosis (MS) Drugs Sales Volume (K Pcs) Forecast by Application in 2022
Table United States Multiple Sclerosis (MS) Drugs Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States Multiple Sclerosis (MS) Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Multiple Sclerosis (MS) Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Multiple Sclerosis (MS) Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories